Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants.


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
16 10 2020
Historique:
received: 23 03 2020
accepted: 15 09 2020
entrez: 17 10 2020
pubmed: 18 10 2020
medline: 29 6 2021
Statut: epublish

Résumé

The genetic and clinical characteristics of breast tumors with germline variants, including their association with biallelic inactivation through loss-of-heterozygosity (LOH) and second somatic mutations, remain elusive. We analyzed germline variants of 11 breast cancer susceptibility genes for 1,995 Japanese breast cancer patients, and identified 101 (5.1%) pathogenic variants, including 62 BRCA2 and 15 BRCA1 mutations. Genetic analysis of 64 BRCA1/2-mutated tumors including TCGA dataset tumors, revealed an association of biallelic inactivation with more extensive deletions, copy neutral LOH, gain with LOH and younger onset. Strikingly, TP53 and RB1 mutations were frequently observed in BRCA1- (94%) and BRCA2- (9.7%) mutated tumors with biallelic inactivation. Inactivation of TP53 and RB1 together with BRCA1 and BRCA2, respectively, involved LOH of chromosomes 17 and 13. Notably, BRCA1/2 tumors without biallelic inactivation were indistinguishable from those without germline variants. Our study highlights the heterogeneity and unique clonal selection pattern in breast cancers with germline variants.

Identifiants

pubmed: 33067557
doi: 10.1038/s42003-020-01301-9
pii: 10.1038/s42003-020-01301-9
pmc: PMC7567851
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0
BRCA2 Protein 0
BRCA2 protein, human 0
Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

578

Références

Nature. 2012 May 16;486(7403):400-4
pubmed: 22722201
PLoS Genet. 2015 Dec 02;11(12):e1005657
pubmed: 26630308
Nat Genet. 2013 Nov;45(11):1293-9
pubmed: 24056718
Nat Genet. 2010 Oct;42(10):851-8
pubmed: 20818383
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
N Engl J Med. 2014 Aug 7;371(6):497-506
pubmed: 25099575
Cancer Cell. 2010 Nov 16;18(5):499-509
pubmed: 21056012
Cancer Res. 2005 Jul 15;65(14):6071-9
pubmed: 16024607
Nature. 2019 Jan;565(7739):312-317
pubmed: 30602793
Oncotarget. 2016 Feb 23;7(8):9600-12
pubmed: 26848529
Cell. 2012 May 25;149(5):994-1007
pubmed: 22608083
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
pubmed: 12829800
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Nat Commun. 2017 Aug 22;8(1):319
pubmed: 28831036
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Nat Rev Cancer. 2016 Sep;16(9):599-612
pubmed: 27515922
Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17773-8
pubmed: 21987798
Nat Commun. 2018 Oct 4;9(1):4083
pubmed: 30287823
Nat Med. 2018 May;24(5):628-637
pubmed: 29713086
N Engl J Med. 2015 Dec 10;373(24):2336-2346
pubmed: 26580448
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
J Natl Cancer Inst. 2011 Feb 16;103(4):334-46
pubmed: 21183737
J Clin Oncol. 2016 May 1;34(13):1460-8
pubmed: 26976419
Am J Hum Genet. 2007 Jul;81(1):114-26
pubmed: 17564968
Nature. 2012 Jun 20;486(7403):405-9
pubmed: 22722202
Bioinformatics. 2012 Feb 1;28(3):423-5
pubmed: 22155870
Clin Cancer Res. 2001 Oct;7(10):3144-50
pubmed: 11595708
Cell. 2014 Dec 4;159(6):1461-75
pubmed: 25433701
N Engl J Med. 2015 Jun 4;372(23):2243-57
pubmed: 26014596
Nature. 2019 Jul;571(7766):576-579
pubmed: 31292550
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Nature. 2012 Apr 04;486(7403):395-9
pubmed: 22495314
Cancer Discov. 2012 Jun;2(6):503-11
pubmed: 22628410
J Clin Oncol. 2015 Feb 1;33(4):304-11
pubmed: 25452441
Nat Genet. 2017 Oct;49(10):1476-1486
pubmed: 28825726
Nucleic Acids Res. 2013 Apr;41(7):e89
pubmed: 23471004
Breast Cancer. 2015 Sep;22(5):462-8
pubmed: 24249303
J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5
pubmed: 14519755
Cancer Sci. 2008 Oct;99(10):1967-76
pubmed: 19016756
Nature. 2016 May 23;534(7607):402-6
pubmed: 27281199
Nat Med. 2020 Oct;26(10):1549-1556
pubmed: 32747829
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
Clin Cancer Res. 2017 Oct 15;23(20):6113-6119
pubmed: 28724667

Auteurs

Yukiko Inagaki-Kawata (Y)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
Department of Breast Surgery, Kyoto University, Kyoto, Japan.

Kenichi Yoshida (K)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.

Nobuko Kawaguchi-Sakita (N)

Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan.

Masahiro Kawashima (M)

Department of Breast Surgery, Kyoto University, Kyoto, Japan.

Tomomi Nishimura (T)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
Department of Breast Surgery, Kyoto University, Kyoto, Japan.

Noriko Senda (N)

Department of Breast Surgery, Kyoto University, Kyoto, Japan.

Yusuke Shiozawa (Y)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.

Yasuhide Takeuchi (Y)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan.
Department of Diagnostic Pathology, Kyoto University, Kyoto, Japan.

Yoshikage Inoue (Y)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.

Aiko Sato-Otsubo (A)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.

Yoichi Fujii (Y)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.

Yasuhito Nannya (Y)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.

Eiji Suzuki (E)

Department of Breast Surgery, Kyoto University, Kyoto, Japan.

Masahiro Takada (M)

Department of Breast Surgery, Kyoto University, Kyoto, Japan.

Hiroko Tanaka (H)

Laboratory of Sequence Analysis, Human Genome Centre, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Yuichi Shiraishi (Y)

Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Kenichi Chiba (K)

Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Yuki Kataoka (Y)

Hospital Care Research Unit/Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.

Masae Torii (M)

Department of Breast Surgery, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.

Hiroshi Yoshibayashi (H)

Department of Breast Surgery, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.

Kazuhiko Yamagami (K)

Department of Breast Surgery, Shinko Hospital, Kobe, Japan.

Ryuji Okamura (R)

Department of Breast Surgery, Yamatotakada Municipal Hospital, Yamatotakada, Japan.

Yoshio Moriguchi (Y)

Department of Breast Surgery, Kyoto City Hospital, Kyoto, Japan.

Hironori Kato (H)

Department of Breast Surgery, Kobe City Medical Center General Hospital, Kobe, Japan.

Shigeru Tsuyuki (S)

Department of Breast Surgery, Osaka Red Cross Hospital, Osaka, Japan.

Akira Yamauchi (A)

Department of Breast Surgery, Kitano Hospital, Osaka, Japan.

Hirofumi Suwa (H)

Department of Breast Surgery, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.

Takashi Inamoto (T)

Tenri Health Care University, Tenri, Japan.

Satoru Miyano (S)

Laboratory of Sequence Analysis, Human Genome Centre, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Seishi Ogawa (S)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan. sogawa-tky@umin.ac.jp.
Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan. sogawa-tky@umin.ac.jp.
Department of Medicine, Centre for Haematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden. sogawa-tky@umin.ac.jp.

Masakazu Toi (M)

Department of Breast Surgery, Kyoto University, Kyoto, Japan. toi@kuhp.kyoto-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH